Evidence map›Paper›PMID 34689796›Full record

ArticleParasites & vectors2021

The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study.

Pyae Linn Aung, Myat Thu Soe, Than Naing Soe, Thit Lwin Oo, Poh Poh Aung, Aung Khin, Aung Thi, Suparat Phuanukoonnon, Kamolnetr Okanurak, Liwang Cui and 2 more

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Mass Drug Administration: Contextual Factor Considerations.The American journal of tropical medicine and hygiene · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Assessment of IgG3 as a serological exposure marker forFrontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Pyae Linn Aung *Myanmar Health Network Organization, Yangon, Myanmar.
Myat Thu Soe *Myanmar Health Network Organization, Yangon, Myanmar.
Than Naing SoeDepartment of Public Health, Ministry of Health, NayPyiTaw, Myanmar.
Thit Lwin OoMyanmar Health Network Organization, Yangon, Myanmar.
Poh Poh AungMyanmar Health Network Organization, Yangon, Myanmar.
Aung KhinMyanmar Health Network Organization, Yangon, Myanmar.
Aung ThiDepartment of Public Health, Ministry of Health, NayPyiTaw, Myanmar.
Suparat PhuanukoonnonDepartment of Social and Environmental Health, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Kamolnetr OkanurakDepartment of Social and Environmental Health, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Liwang CuiDivision of Infectious Diseases and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA.
Myat Phone KyawMyanmar Health Network Organization, Yangon, Myanmar. kyaw606@gmail.com.
Daniel M ParkerDepartment of Population Health and Disease Prevention, Department of Epidemiology, University of California, Irvine, CA, USA. dparker1@hs.uci.edu.ORCID http://orcid.org/0000-0002-5352-7338
Myanmar Oxford Clinical Research Unit · MMMahidol University · THMinistry of Health and Sports · MMCalifornia Health and Human Services Agency · USUniversity of South Florida · US

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
NIAID NIH HHS U19 AI089672NIH HHS U19AI089672
6 · The paper itself

Abstract

backgroundRadical cure of the Plasmodium vivax latent liver stage is required to effectively manage vivax malaria. Targeted mass treatment with primaquine may be an effective mechanism for reducing reservoirs of the disease. Since community engagement and high coverage are essential for mass treatment programs, this study aimed to determine the acceptability of mass primaquine treatment in a targeted community in a northern Myanmar township.

methodsA cross-sectional mixed-methods study was deployed among household leaders in July 2019. Face-to-face interviews using structured questionnaires and standardized qualitative guidelines were conducted to gather information. Descriptive and inferential statistics, including logistic regression models, were applied.

resultsAmong 609 study respondents, > 90% agreed to participate in an upcoming targeted mass primaquine treatment (TPT) program. Factors contributing to higher odds of acceptability of the program were older age [adjusted odds ratios (aOR): 2.38, 95% confidence intervals (CI) 1.08-8.96], secondary education level (aOR: 3.99, 95% CI 1.12-20.01), having good knowledge of malaria (aOR: 2.12, 95% CI 1.04-4.76), experiencing malaria within the family (aOR: 1.92, 95% CI 1.14-5.13), and believing eliminating malaria from the village is possible (aOR: 2.83, 95% CI 1.07-4.07). Furthermore, 50 community respondents, 6 midwives, and 4 public health staff (grade II) participated in the qualitative component of the study. Many thought that TPT seemed feasible and stressed that high coverage of underserved groups and health education are needed before commencing the activity.

conclusionsMost respondents agreed to participate in the proposed mass treatment campaign. Older people with secondary education level and those who had experienced malaria within their families were most likely to report willingness to participate. These same individuals may be important in the community engagement process to increase community acceptance of the program.

Indexed as

AdolescentAdultAgedAged, 80 and overAntimalarialsCross-Sectional StudiesDisease EradicationDrug Administration ScheduleFamily CharacteristicsFemaleHumansMalaria, VivaxMaleMass Drug AdministrationMiddle AgedMyanmarAntimalarialsPrimaquineAcceptabilityMixed-methodsMyanmarPrimaquineTargeted mass treatment

Identifiers

PMID34689796
PMCPMC8543804
OpenAlexW3211316706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.